The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Allogene Therapeutics, Inc(NASDAQ:ALLO) 
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candi...
Website: http://www.allogene.com
Founded: 2017
Full Time Employees: 264
Sector: Healthcare
Industry: Biotechnology
Allogene Therapeutics Days Payable Outstanding ttm (DPO)
Allogene Therapeutics Days Receivable Outstanding ttm (DSO)
Allogene Therapeutics Days Inventory Outstanding ttm (DIO)
Allogene Therapeutics Op Cashflow Per Share ttm
Allogene Therapeutics Free Cashflow Per Share ttm
Allogene Therapeutics Cash Per Share ttm
Allogene Therapeutics P/S ratio ttm
Allogene Therapeutics (GAAP) P/E ratio ttm
Allogene Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.